收费全文 | 29270篇 |
免费 | 2340篇 |
国内免费 | 81篇 |
耳鼻咽喉 | 435篇 |
儿科学 | 949篇 |
妇产科学 | 615篇 |
基础医学 | 4083篇 |
口腔科学 | 398篇 |
临床医学 | 3419篇 |
内科学 | 5695篇 |
皮肤病学 | 338篇 |
神经病学 | 3154篇 |
特种医学 | 957篇 |
外科学 | 3908篇 |
综合类 | 358篇 |
一般理论 | 29篇 |
预防医学 | 3026篇 |
眼科学 | 637篇 |
药学 | 1861篇 |
中国医学 | 27篇 |
肿瘤学 | 1802篇 |
2023年 | 300篇 |
2022年 | 415篇 |
2021年 | 918篇 |
2020年 | 560篇 |
2019年 | 928篇 |
2018年 | 994篇 |
2017年 | 710篇 |
2016年 | 735篇 |
2015年 | 765篇 |
2014年 | 1034篇 |
2013年 | 1480篇 |
2012年 | 2231篇 |
2011年 | 2183篇 |
2010年 | 1182篇 |
2009年 | 1005篇 |
2008年 | 1655篇 |
2007年 | 1750篇 |
2006年 | 1768篇 |
2005年 | 1644篇 |
2004年 | 1360篇 |
2003年 | 1388篇 |
2002年 | 1279篇 |
2001年 | 366篇 |
2000年 | 318篇 |
1999年 | 351篇 |
1998年 | 285篇 |
1997年 | 232篇 |
1996年 | 218篇 |
1995年 | 168篇 |
1994年 | 140篇 |
1993年 | 143篇 |
1992年 | 224篇 |
1991年 | 224篇 |
1990年 | 214篇 |
1989年 | 174篇 |
1988年 | 161篇 |
1987年 | 188篇 |
1986年 | 147篇 |
1985年 | 154篇 |
1984年 | 140篇 |
1983年 | 128篇 |
1982年 | 104篇 |
1981年 | 113篇 |
1980年 | 92篇 |
1979年 | 99篇 |
1978年 | 103篇 |
1977年 | 101篇 |
1976年 | 92篇 |
1974年 | 87篇 |
1972年 | 69篇 |
Methods: Two previously published datasets (n?=?153 and n?=?641, respectively) from outpatient neuropsychological evaluations were used to test Dunham and Denney’s algorithm, and to assess concordance of failure rates with the Test of Memory Malingering and the forced choice measure of the California Verbal Learning Test, two commonly used performance validity tests.
Results: In both datasets, none of the four cutoff scores for failure on the MSVT (70%, 75%, 80%, or 85%) identified a poor validity group with proportionally aligned failure rates on other freestanding measures of performance validity. Additionally, the protocols with probable impairment did not differ from those with poor validity on cognitive measures.
Conclusions: Despite what appeared to be a promising approach to evaluating failure on the easy MSVT subtests when clinical data are unavailable (as recommended in the advanced interpretation program, or advanced interpretation [AI], of the MSVT), the current findings indicate the AI remains the gold standard for doing so. Future research should build on this effort to address shortcomings in measures of effort in neuropsychological evaluations. 相似文献
Objective
The “Centre Hospitalier Francois Dunan” is located on an isolated island and ensures patients care in hemodialysis thanks to telemedicine support. Many research studies have demonstrated the importance of hemodialysis fluids composition to reduce morbidity in patients on chronic hemodialysis. The aim of this study was to identify the risks inherent in the production of dialysis fluids in a particular context, in order to set up an improvement action plan to improve risk control on the production of dialysis fluids.Methods
The risk analysis was conducted with the FMECA methodology (Failure Mode, Effects and Criticality Analysis) by a multi professional work group. Three types of risk have been reviewed: technical risks that may impact the production of hemodialysis fluids, health risks linked with chemical composition and health risks due to microbiological contamination of hemodialysis fluids.Results
The work group, in close cooperation with the expert staff of the dialysis center providing telemedicine assistance, has developed an action plan in order to improve the control of the main risks brought to light by the risk analysis.Conclusion
The exhaustive analysis of the risks and their prioritisation have permitted to establish a relevant action plan in this improving quality of dialysis fluids approach. The risk control of dialysis fluids is necessary for the security of dialysis sessions for patients, even more when these sessions are realized by telemedicine in Saint-Pierre-et-Miquelon. 相似文献Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.